Nemluvio (nemolizumab-ilto) — United Healthcare
prurigo nodularis
Initial criteria
- Diagnosis of prurigo nodularis
- Patient is not receiving Nemluvio in combination with Dupixent for treatment of the same indication
Reauthorization criteria
- Documentation of positive clinical response to Nemluvio therapy
- Patient is not receiving Nemluvio in combination with Dupixent for treatment of the same indication
Approval duration
12 months